Achieve Life Sciences Past Earnings Performance
Past criteria checks 0/6
Achieve Life Sciences's earnings have been declining at an average annual rate of -24.3%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-24.3%
Earnings growth rate
69.3%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Achieve Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -30 | 11 | 16 |
30 Sep 23 | 0 | -36 | 11 | 22 |
30 Jun 23 | 0 | -42 | 11 | 29 |
31 Mar 23 | 0 | -44 | 11 | 31 |
31 Dec 22 | 0 | -42 | 11 | 30 |
30 Sep 22 | 0 | -38 | 11 | 26 |
30 Jun 22 | 0 | -32 | 10 | 21 |
31 Mar 22 | 0 | -33 | 10 | 23 |
31 Dec 21 | 0 | -33 | 9 | 24 |
30 Sep 21 | 0 | -31 | 9 | 22 |
30 Jun 21 | 0 | -28 | 9 | 19 |
31 Mar 21 | 0 | -19 | 8 | 11 |
31 Dec 20 | 0 | -15 | 8 | 7 |
30 Sep 20 | 0 | -13 | 7 | 6 |
30 Jun 20 | 0 | -13 | 7 | 6 |
31 Mar 20 | 0 | -14 | 7 | 7 |
31 Dec 19 | 0 | -16 | 7 | 10 |
30 Sep 19 | 0 | -17 | 7 | 10 |
30 Jun 19 | 0 | -16 | 7 | 10 |
31 Mar 19 | 0 | -16 | 7 | 9 |
31 Dec 18 | 0 | -13 | 7 | 6 |
30 Sep 18 | 0 | -13 | 7 | 6 |
30 Jun 18 | 0 | -16 | 7 | 5 |
31 Mar 18 | 0 | -13 | 5 | 4 |
31 Dec 17 | 0 | -11 | 4 | 3 |
30 Sep 17 | 0 | -7 | 2 | 1 |
31 Mar 17 | 0 | -1 | 1 | 0 |
31 Dec 16 | 0 | -1 | 1 | 0 |
Quality Earnings: SP4P is currently unprofitable.
Growing Profit Margin: SP4P is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SP4P is unprofitable, and losses have increased over the past 5 years at a rate of 24.3% per year.
Accelerating Growth: Unable to compare SP4P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SP4P is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: SP4P's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.